Safety Study of Dasatinib With Bortezomib (Velcade®) and Dexamethasone for Multiple Myeloma
Stopped early · Phase 1
Conditions studied: Multiple Myeloma
In brief
The purpose of this study is to determine the safety and tolerability of dasatinib with bortezomib in the treatment of relapsed or refractory multiple myeloma.
Key facts
- Study ID
- NCT00560352
- Run by
- Bristol-Myers Squibb
- People needed
- 16
- Starts
- 2008-02-01
- Expected to finish
- 2011-02-01
- Last updated by the study team
- 2017-03-13
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Orlando Health, Inc. M.D. Anderson Cancer Center Orlando — Orlando, Florida, United States
- Winship Cancer Institute, Emory University — Atlanta, Georgia, United States
- Local Institution — Nantes, Cedex 1, France
- Local Institution — Lille, France
- Local Institution — Bari, Italy
- Local Institution — Bologna, Italy
- Local Institution — Salamanca, Spain
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.